retatrutide parkinson's disease trial nct The NADPARK study: A randomized phase I of nicotinamide riboside supplementation in Emerging therapies in Parkinson disease

After we eat, GLP-1 (made in our intestines) helps signal fullness, slows the rate at which food leaves the stomach, and coordinates insulin and glucagon release to keep blood sugar levels in check

Brain Sci 13:1503 Arillotta D, Floresta G, Papanti Pelletier GD et al (2024) Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach

Entire Reddit channels dedicated to talking about GLP-1s as Autoimmune disease miracles noting improvements in symptoms on a variety of GLP-1 doses

All adverse event data in this article comes from two sources: the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) and the TRIUMPH Phase 3 program data presented at medical conferences

This ensures that as your appetite decreases, the quality of your nutrition increases, preventing the fatigue and muscle loss often associated with unmonitored GLP-1 use